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Abstract
Identification of biomarkers that predict responses to hypomethylating agents (HMAs) will allow optimal strategies for
epigenetic therapy in myelodysplastic syndromes (MDS) to be established. Serum miR-21 was quantitatively measured in 58
MDS patients treated with HMAs and 14 healthy controls. Serum miR-192 was an internal control, and diagnostic
performance was evaluated according to receiver operating characteristics (ROCs). ROC analysis indicated that serum miR-
21 levels differentiated responders from non-responders with an area under the curve of 0.648 (95% confidence, 0.49 to
0.72). The baseline level of serum miR-21 was significantly lower in the responder group than in the non-responder group
(P= 0.041). The overall response rate (ORR) of the high miR-21 group was significantly lower than that of the low miR-21
group (41.2 vs. 73.2%, P = 0.021). Progression-free survival (PFS) was significantly inferior in the high group versus the low
group (14.0 vs. 44.5 months, P= 0.001). Multivariate analyses revealed that the initial serum miR-21 level (P= 0.001) and
circulating blasts (P= 0.007) were prognostic factors for PFS. Serum miR-21 level was significantly associated with ORR and
PFS in MDS patients treated with HMAs. Although validation with a large prospective study is required, serum miR-21 is a
potential biomarker of epigenetic therapy in MDS patients.
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Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group
of clonal disorders characterized by bone marrow failure, dysplasia
of one or more of the myeloid blood cell lineages, and an increased
risk of developing acute myeloid leukemia [1]. Recently, epigenetic
therapy with hypomethylating agents (HMAs) has demonstrated
clinical effectiveness for MDS [2–4]. For instance, azacitidine
(AZA) can improve hematologic parameters, delay transformation
into acute myeloid leukemia (AML), and improve quality of life
and survival in comparison with supportive care [3]. However,
response to HMA differs between patients, with overall response
rates ranging from 40 to 60% [5,6]. If response to HMA can be
predicted, treatment outcomes can be improved by selecting MDS
patients in whom HMA are likely to be beneficial and by
developing risk-adapted therapeutic strategies. Unfortunately,
biomarkers that predict response or survival following treatment
with AZA or decitabine (DAC) remain largely unidentified and
debated in patients with MDS. Clinical parameters, including
bone marrow blasts, abnormal karyotype, World Health Organi-
zation (WHO) classification-based prognostic scoring system
(WPSS), and interval from diagnosis to the initiation of HMA,
were reported to be associated with response to HMA [7,8].
However, these findings were not confirmed in other studies [9].
Further, associations with survival outcomes were not demon-
strated. Molecular parameters, such as mutations in TET2 [10],
DNMT3A [11], or ASXL1 [11], induction of p53-inducible
ribonucleotide reductase [12], reactivation of phosphoinositide
phospholipase Cb gene [13], and gene methylation profile [14],
correlated with clinical response to HMA.
MicroRNAs (miRs) are short noncoding RNAs that modulate
gene expression by negatively regulating stability or translational
efficiency of the target mRNA [15–17]. MiRs have critical roles in
developmental processes, hematopoiesis, cell differentiation, pro-
liferation, and apoptosis [18–20]. In addition, deregulation of
miRs has been shown to contribute to the development of a variety
of tumors, such as leukemia [21,22], neuroblastoma [23], breast
cancer [18], and lung cancer [24]. Aberrant expression of miRs
was shown to have crucial roles in tumor progression and
development of chemoresistance [25–28]. For these reasons,
miRNA expression analyses have been applied to tumor diagnosis,
treatment, and prognostic prediction [27–29].
MiRs can be consistently detected and quantitatively measured
by real-time polymerase chain reaction in plasma and serum
samples, which are easily obtained from cancer patients [29–32].
Thus, circulating miRs are potentially suitable biomarkers for a
variety of cancers. In this study, we evaluated the potential of
serum miR-21 as a biomarker for predicting response to HMA in
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MDS patients. MiR-21, a representative oncogenic miRNA
[29,33–35], has prognostic significance in many cancers [27,28]
and can modulate sensitivity to chemotherapeutic agents [24–
26,28]. There is increasing evidence that circulating miR-21 may
be a useful biomarker in various cancers [29,30,36]. For example,
high levels of serum miR-21 in patients with diffuse large cell
lymphoma were related to lymphoma recurrence and patient
survival [36]. Further, plasma miR-21 expression was related to
the sensitivity of non-small cell lung cancer to platinum-based
chemotherapy [24].
In the present study, we demonstrate for the first time that
serum miR-21 level is a potential biomarker associated with
clinical response to epigenetic treatment in MDS. Progression-free
survival (PFS) following HMA treatment was significantly shorter
in patients with high serum miR-21 levels. Circulating miR-21
should be further validated as a biomarker in MDS through a
prospective study with a large cohort.
Methods
Patients and Samples
We analyzed clinical records and samples from 58 patients with
MDS treated with HMA between January 2006 and December
2011 at Yonsei University Severance Hospital and Chonnam
National University Hospital. Forty-six patients received AZA,
and 12 received DAC. For each cycle, AZA and DAC were
administered subcutaneously at a dose of 75 mg/m2/day for 7
days and intravenously at a dose of 20 mg/m2/day for 5 days,
respectively. HMAs were administered until disease progression or
intolerable toxicities developed. All patients were enrolled onto
protocols approved by the Institutional Review Board of
Severance Hospital and provided written informed consent in
accordance with the Declaration of Helsinki.
Responses
Response was assessed by modified International Working
Group (IWG2006) response criteria [37]. Overall response rate
(ORR) included rates for complete response (CR), marrow CR
(mCR), partial response (PR), and hematologic improvement (HI).
Overall survival (OS) and PFS were measured from the date of
initiation of HMA to death or censored at the time of last contact
and to progression of disease or leukemic transformation,
respectively.
MicroRNA Quantification by Quantitative Real-time
Polymerase Chain Reaction (qRT-PCR)
The purity and concentration of RNA isolated using mirVana
PARIS kit (Ambion Inc., Austin, TX) were evaluated with a
NanoDrop ND-1000 spectrophotometer (NanoDrop Technolo-
gies, Rockland, DE, USA). Serum miR-21 quantification was
performed with the SYBR-Green qRT-PCR assay on an ABI
7500 RT-PCR instrument (Applied Biosystems, Foster City, CA).
The amplification profile was as follows; denaturing at 95uC for
10 min, 40 cycles at 95uC for 15 sec, 60uC for 30 sec, and 72uC
for 1 sec. All reactions were run in triplicate. Relative levels of
miRs were quantified by the comparative CT (22DDCT) method, in
which DCt=mean CtmiRNA2mean Ctinternal control. The cycle
threshold (Ct) was defined as the number of cycles required for the
fluorescent signal to cross the threshold in qRT-PCR.
Evaluation of Internal Controls for Serum miR-21
Quantification
To select a reliable internal reference miR, we evaluated the
abundance and stability of three endogenous control miRs, miR-
192, miR-16, and miR-93, in the sera of 16 MDS patients and 8
healthy donors. 30,32,38 Gene expression levels were analyzed in
triplicate and comparative CT method algorithms. If expression
levels were equivalent between groups, the stabilities of candidate
reference genes were compared by the geNorm software (version
3.4) method [39].
Statistical Analysis
Characteristics of patients are presented as median and range
for continuous factors and frequencies for discrete factors. The x2-
test was used for comparison of categorical variables such as
prognostic factors for treatment response. The sensitivity and
specificity of the optimum cut-off point were defined as those
values that maximized the area under the receiver operating
characteristic curve (AUC). The optimal cut-off point for miR-21
was determined by the Youden index (sensitivity+specificity-1).
The OS and PFS results in low and high miR-21 group were
estimated by the Kaplan-Meier method and compared by the log-
rank test. Multivariate analyses were performed by Cox propor-
tional-hazards regression analysis. P value less than 0.05 denoted
statistical significance. All analyses were performed with the SPSS
18.0 statistical package (SPSS Inc., Chicago, IL).
Results
Patient Characteristics
The study population included 58 patients (38 males and 20
females) with a median age of 67 years (range, 35–83 years). The
characteristics of the patients are summarized in Table 1.
Diagnosis according to WHO criteria included five (8.6%) cases
of refractory anemia (RA) or RA with ringed sideroblasts, 16
(27.6%) cases of RA with multilineage dysplasia, 11 (19.0%) cases
of RA with excess blasts-1 (RAEB-1), 20 (34.5%) cases of RAEB-2,
and six (10.3%) of MDS-unclassified. Median time from the
diagnosis to HMA initiation was 0.7 months (range, 0–5.8
months). Cytogenetic risk was good in 34 (58.6%), intermediate
in eight (13.8%), and poor in 8 (13.8%) patients. Karyotyping was
unsuccessful in eight cases. The median number of cycles
administered was six (range, 1–16). IPSS was low in two (3.4%),
intermediate-1 (Int-1) in 23 (39.7%), intermediate-2 (Int-2) in 19
(32.8%), high in six (10.3%), and undetermined in eight (13.8%)
cases. Thirty-three (56.9%) cases were transfusion-dependent.
WPSS risk was low in four (6.9%), intermediate in 15 (25.9%),
high in 26 (44.8%), and very high in five (8.6%) patients. Forty-six
(79.3%) patients received AZA and 12 (20.7%) received DAC.
None of the patients received chemotherapy or hematopoietic
stem cell transplantation prior to the study.
Selection of the Internal Control for Serum miR-21
Quantification
In order to select a reliable internal control for quantification of
serum miR-21 in MDS, we examined miR-192, miR-16, and
miR-93 levels by qRT-PCR as described in Design and Methods.
Expression levels of serum miR-16, miR-93, and miR-192 did not
differ between normal donors, MDS patients prior to HMA
therapy, and MDS patients who received four cycles of HMA
(Figure 1A). However, the median Ct values of miR-16 (33.1;
range, 32.0–34.1) and miR-93 (31.7; range, 30.5–33.0) were high
in normal donors, MDS patients prior to HMA therapy, and MDS
miR-21 as a Response Predictor to HMT in MDS
PLOS ONE | www.plosone.org 2 February 2014 | Volume 9 | Issue 2 | e86933
patients who received four cycles of HMA. In contrast, the Ct
values of serum miR-192 were low in all three groups (median
25.9; range 25.6–26.4). Stability values of the three candidate
reference miRNAs were calculated by geNorm analyses. GeNorm
analyses showed that M values of miR-16 and miR-93 were 0.007
and 0.009, respectively. miR-192 had the lowest M value of 0.003,
indicating that miR-192 was stably expressed in serum (Figure 1B).
Thus, miR-192 was selected as an internal control miRNA for
quantifying serum miR-21 in MDS patients in this study.
Table 1. Overall characteristics of patients and stratification according to serum miR-21 level.
Serum miR-21
Variable Overall (n = 58) Low (n=41) High (n =17) P-value
Age (y), median(range) 67 (35–83) 67 (36–83) 65 (35–78) 0.950
Male, n(%) 38 (65.5) 29 (70.7) 9 (52.9) 0.194
WHO subtype, n(%) RA/RARS 4 (6.9)/1(1.7) 3 (7.3)/0 1 (5.9)/1(5.9) 0.109
RCMD 16 (27.6) 10 (24.4) 6 (35.3)
RAEB-1 11 (19.0) 5 (12.2) 6 (35.3)
RAEB-2 20 (34.5) 18 (43.9) 2 (11.8)
MDS-U 6 (10.3) 5 (12.2) 1 (5.9)
Karyotype risk, n(%)a Good 34 (58.6) 26 (63.4) 8 (47.1) 0.207
INT 8 (13.8) 6 (14.6) 2 (11.8)
Poor 8 (13.8) 4 (9.8) 4 (23.5)
N/A 8 (13.8) 5 (12.2) 3 (17.6)
Hemoglobin (g/dL), median(range) 8.4 (4.8–12.4) 8.5(4.8–12.4) 8.0 (5.5–10.5) 0.225
Neutrophil (x109/L), median(range) 0.93 (0.05–41.15) 0.91 (0.05–41.15) 1.04 (0.16–4.76) 0.701
Platelets (x109/L), median(range) 72 (5–543) 75 (6–548) 69 (5–177) 0.898
PB blast (%), median(range) 0, (0–12) 0, (0–5) 0 (0–12) 0.424
BM blast (%), median(range) 5.1 (0–18.8) 2.0 (0–18.8) 0.2 (0–18.4) 0.173
Interval from diagnosis to HMA therapy, months,
median(range)
0.7 (0–5.8) 0.9 (0–5.8) 0.4 (0–5.2) 0.457
IPSS, n(%) Low 2 (3.4) 1 (2.4) 1 (5.9) 0.715
INT-1 23 (39.7) 18 (43.9) 5 (29.4)
INT-2 19 (32.8) 13 (31.7) 6 (35.3)
High 6 (10.3) 4 (9.8) 2 (11.8)
N/A 8 (13.8) 5 (12.2) 3 (17.6)
WPSS,n(%) Low 4 (6.9) 3 (7.3) 1 (5.9) 0.870
INT 15 (25.9) 12 (29.3) 3 (17.6)
High 26 (44.8) 18 (43.9) 8 (47.1)
Very high 5 (8.6) 3 (7.3) 2 (11.8)
N/A 8 (13.8) 5 (12.2) 3 (17.6)
Transfusion dependence, n(%)b 33 (56.9) 22 (53.7) 11 (64.7) 0.439
HMA treatment, n(%) Azacitidine 46 (79.3) 33 (80.5) 13 (76.5) 0.733
Decitabine 12 (20.7) 8 (19.5) 4 (23.5)







AlloHCT after HMA therapy, n(%) 11 (19.0) 9 (22.0) 2 (11.8) 0.372
Follow-up months,median(range) 15.4 (0.7–66.4) 14.9 (3.7–66.4) 17.1 (0.7–46.0) 0.871
Alive, n(%) 34 (58.6) 25 (61.0) 9 (52.9) 0.484
Leukemic transformation, n(%) 1 (1.7) 1 (2.4) 0 0.184
Abbreviations: miR-21, microRNA-21; WHO, World Health Organization; RA, refractory anemia;
RARS, RA with ring sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, RCMD with ring sideroblasts; RAEB, refractory anemia with excess
blasts; MDS-U, myelodysplastic syndromes unclassifiable; PB, peripheral blood; BM, bone marrow; HMA, hypomethylating agent; IPSS, International Prognostic Scoring
System; NA, not available; WPSS, WHO classification-based Prognostic Scoring System; alloHCT, allogeneic hematopoietic stem cell transplant, INT, intermediate.
aCytogenetic: Good =normal, -Y alone, del(5q) alone, del(20q) alone; Poor = complex ($3 abnormalities) or chromosome 7 anomalies; Intermediate = other
abnormalities.
bAt least 2 units of red blood cell transfusion during 8 weeks prior to HMA initiation.
doi:10.1371/journal.pone.0086933.t001
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Clinical Characteristics according to Serum miR-21 Levels
Serum miR-21 expression levels were examined by qRT-PCR
in 58 patients with MDS and 14 healthy volunteers. The relative
level of serum miR-21 expression was significantly higher in
healthy donors than in MDS patients at diagnosis (4.204764.1479
vs. 0.941460.8690, P,0.001, Figure 2A). Because serum miR-21
levels showed heterogeneity among patients, we arbitrarily
classified the patients with serum miR-21 levels (22DDCT) greater
than the cut-off value of 1.2613 as the high-miR-21 group (n= 17)
and the remaining patients as the low-miR-21 group (n= 41) as
described in Design and Methods. The median value of serum
miR-21 in the high-miR-21 group was significantly higher than
that of the low-miR-21 group (1.7380 vs. 0.8290, P,0.001). There
were no differences in patient age, sex, baseline hemoglobin levels,
Figure 1. Expression and stability of reference gene candidates in the sera of healthy donors and patients with MDS. (A)
Quantification (Ct) of candidate reference miRNAs (miR-192, miR-16, and miR-93) in serum samples of healthy donors and MDS patients corrected for
efficiency and two interpolate controls are shown. Box plots represent lower and upper quartiles with the median depicted with a horizontal line.
Whiskers depict the 10th and 90th percentiles. Differences in serum levels of candidate miRNAs were not found between healthy donors (white box),
MDS patients prior to HMA therapy (gray box), and MDS patients treated with four courses of HMA therapy (black box). (B) Average expression
stability values for candidate reference miRs in MDS patients, which were calculated by the geNorm algorithm, are shown as a bar graph and with
actual values. High expression stability is indicated by a low stability value. MDS, myelodysplastic syndromes; miRNAs, microRNAs; HMA,
hypomethylating agents.
doi:10.1371/journal.pone.0086933.g001
Figure 2. Differences in baseline serummiR-21 expression levels. (A) Difference in serum miR-21 levels between healthy donors and patients
with MDS prior to HMA therapy. Expression levels of serum miR-21 were normalized to the reference gene, miR-192, which was selected as described
in Design and Methods. (B) Difference in baseline serum miR-21 levels between responders to HMA therapy and non-responders. Bar graph and
whisker indicate the median value and standard deviation of serum miR-21 levels, respectively. Significance is indicated by the P value.
doi:10.1371/journal.pone.0086933.g002
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Figure 3. Receiver operating characteristics (ROCs) curve analysis for the diagnostic value of miR-21. The area under the ROC curve
(AUC) was 0.648 (95% CI: 0.49 to 0.72).
doi:10.1371/journal.pone.0086933.g003
Table 2. Response to HMA therapy according to serum miR-21 level.
Serum miR-21
Overall (n = 58) Low (n=41) High (n=17) P-value
HMA cycles administrated (range) 6 (1–16) 7 (1–12) 6 (3–16) 0.474
HMA cycles for best response (range) 4 (2–14) 4 (2–12) 4 (2–14) 0.632
Time to response, months (range) 4.5 (1.0–50.5) 4.3 (1.0–50.5) 5.1 (1.0–23.8) 0.956
Response by IWG 2006 criteria, n (%) CR/PR 4 (6.8) 3 (7.3) 1 (5.9) 0.542
HMA cycles administrated (range) mCR 3 (5.2) 3 (7.3) 0
SD with HI 30 (51.7) 24 (58.5) 6 (35.3)
SD without HI 14 (24.1) 6 (14.6) 8 (47.1)
PD/Failure 7 (12.0) 5 (12.1) 2 (11.8)
CR/PR 4 (6.8) 3 (7.3) 1 (5.9)
mCR 3 (5.2) 3 (7.3) 0
ORR (CR+PR+mCR+SD with HI) 37 (63.8) 30 (73.2) 7 (41.2) 0.012
Response duration, months (range) 39.1 (28.5–49.8) 47.2 (36.6–58.0) 18.1 (7.6–28.6) 0.067
Abbreviations: miR-21, microRNA-21; HMA, hypomethylating agent; IWG, International Working Group; CR, complete response; PR, partial response; mCR, marrow CR;
SD, stable disease; HI, hematologic improvement; PD, progressive disease; ORR, overall response rate.
Results are shown as n (%) or median value.
doi:10.1371/journal.pone.0086933.t002
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neutrophils, platelet counts, percentages of blasts in the peripheral
blood or bone marrow, interval from diagnosis to HMA initiation,
and transfusion dependency ($4 RBC units/8 weeks) between the
high-miR-21 and low-miR-21 groups (Table 1). No significant
differences in WHO diagnosis, cytogenetic risk, IPSS risk
categories, and WPSS risk were found between the high-miR-21
and low-miR-21 groups. The relative proportions of patients who
received AZA or DAC as HMA treatment were comparable
between the two groups (Table 1). Follow-up period and the
proportion of patients who received allogeneic hematopoietic stem
cell transplantation after HMA therapy were similar between the
groups.
Relationship between Serum miR-21 Levels and
Response to HMA
Response to HMA is summarized in Table 2. The ORR, which
included CR, mCR, PR, and SD with HI, was 63.8%. CR was
achieved in two cases (3.4%), PR in two (3.4%), mCR in three
(5.2%), and SD with HI in 30 cases (51.7%). The median time to
response was 4.5 months (range, 0.2–50.5 months), and the
median duration of response was 39.1 months (range, 28.5–49.8
months). ROC curve analyses were performed to evaluate whether
serum miR-21 is a potential marker for predicting response to
HMA. ROC analysis indicated that serum miR-21 differentiated
responders from non-responders with an AUC of 0.648 (95%
confidence interval [CI], 0.49 to 0.72; Figure 3). At the cut-off
value of 1.2613 for serum miR-21 level (22DDCT), the optimal
sensitivity and specificity were 83.3% (95% CI: 68.6–93.3%) and
45.8% (95% CI: 25.5–67.1%), respectively.
Response to HMA according to serum miR-21 level is shown in
Figure 2B and Table 2. The baseline level of serum miR-21 was
significantly lower in the responder group than in the non-
responder group (0.941760.6349 vs. 1.144360.7707, P=0.041,
Figure 2B). ORR in the high-miR-21 group was significantly lower
Table 3. Univariate analysis for overall response rate, overall survival, and progression-free survival.





Age, years ,65 17 (63.0) 0.772 22.1 0.942 24.7 0.727
$65 20 (66.7) 26.7 44.1
Neutrophils (6109/L) ,1.0 21 (70.0) 0.263 32.6 0.596 44.1 0.118
$1.0 15 (55.6) 30.6 18.4
Hemoglobin (g/dL) ,9 22 (64.7) 0.863 19.1 0.058 45.0 0.980
$9 15 (62.5) 44.7 28.7
WHO subtype RCMD/RCMD-RS 11 (61.1) 0.334 44.1 0.278 31.0 0.329
RAEB-1 6 (54.5) 12.6 28.7
RAEB-2 11 (61.1) 22.0 12.7
RA/RARS/MDS-U 9 (81.8) 26.6 38.6
Cytopenia 0–1 lineage 11 (64.7) 0.876 39.7 0.257 24.7 0.929
2–3 lineage 25 (62.5) 28.6 29.7
Marrow blasts (%) ,15 33 (63.5) 0.878 16.0 0.129 12.3 0.947
$15 4 (66.7) 5.0 5.3
Presence of circulating blasts Yes 2 (28.6) 0.040 16.7 0.200 8.2 ,0.001
No 35 (68.6) 26.7 29.7
IPSS Cytogenetic Good 27 (79.4) 0.029 26.0 0.110 13.6 0.429
Intermediate 3 (37.5) 22.1 9.2
Poor 4 (50.0) 12.7 8.2
N/A 3 (37.5) 45.6 16.1
IPSS Low/Int-1 17 (68.0) 1.000 26.6 0.125 31.0 0.995
Int-2/High 17 (68.0) 19.1 28.7
WPSS Low/Int 14 (73.6) 0.500 44.1 0.057 31.0 0.508
High/Very high 20 (64.5) 19.1 28.7
RBC transfusion dependency Yes 21 (63.6) 0.977 44.1 0.408 24.7 0.989
No 16 (64.0) 22.1 45.5
AlloHCT after HMA therapy Yes 31 (83.7) 0.478 33.6 0.537 35.3 0.330
No 6 (16.3) 31.7 29.3
Serum miR-21 level Low 30 (73.2) 0.021 26.7 0.644 45.5 0.001
High 7 (41.2) 44.1 14.0
Abbreviations: ORR, overall response rate; OS, overall survival; PFS, progression-free survival; RA, refractory anemia; RARS, RA with ring sideroblasts; RCMD, refractory
cytopenia with multilineage dysplasia; RCMD-RS, RCMD with ring sideroblasts; RAEB, refractory anemia with excess blasts; MDS-U, myelodysplastic syndromes
unclassifiable; IPSS, International Prognostic Scoring System; NA, not available; WPSS, WHO classification-based Prognostic Scoring System; RBC, red blood cell; alloHCT,
allogeneic hematopoietic stem cell transplant; miR-21, microRNA-21.
doi:10.1371/journal.pone.0086933.t003
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than in the low-miR-21 group (41.2% vs. 73.2%, P= 0.012).
However, the number of HMA cycles administered was compa-
rable between the two groups. The number of HMA cycles
required for achieving best response was also similar between the
groups. The frequency of MDS patients who did not respond,
which included cases of SD without HI, progression of disease, or
AML transformation, was higher in the high-miR-21 group (10/
17, 58.9%) compared to the low-miR-21 group (11/41, 26.7%,
P=0.012). The median duration of response in the high-miR-21
group was shorter (18.1 months, range, 7.6–28.6 months) than in
the low-miR-21 group (47.2 months, range, 36.5–58.0 months),
although statistical significance was not observed (P=0.067,
Table 2). In addition to serum miR-21 levels, cytogenetic risk
(P=0.029) and the presence of circulating blasts at diagnosis
(P=0.040) were significantly associated with low response rate to
HMA (Table 3). However, neither patient age, baseline neutro-
phils, platelet counts, number of cases with cytopenia, percentage
of bone marrow blasts, IPSS risk, WPSS risk, nor red blood cell
transfusion dependence were associated with response to HMA.
Multivariate Cox regression indicated that only cytogenetic risk
was significantly correlated with ORR (HR=0.575; 95% CI,
0.340 to 0.974; P=0.040) (Table 4).
Survival According to Serum miR-21 Levels
The median follow-up period was 15.4 months (range, 0.7–66.4
months), and 34 patients survived. Figure 2 shows Kaplan-Meier
curves for OS and PFS stratified according to baseline serum miR-
21 level. The median OS for the high-miR-21 group (22.6 months,
95% CI 12.4–32.7 months) was shorter than that of the low-miR-
21 group (45.0 months, 95% CI 15.3–74.6 months), although it
was not statistically different (P=0.644, Figure 4A). None of the
clinical parameters that we analyzed correlated with OS in HMA-
treated MDS patients (Table 3). However, median PFS was
significantly shorter in patients with high serum miR-21 than in
patients with low serum miR-21 (14.0 vs. 44.5 months, P=0.001,
Table 3 and Figure 4B). The one-year PFS rate was significantly
higher in the low-miR-21 group compared with the high-miR-21
group (80.8% vs. 57.0%, P=0.001). Eleven patients received
allogeneic hematopoietic stem cell transplantation after HMA
treatment. However, censoring at the time of transplant did not
affect PFS outcomes (P=0.330, data not shown). In addition to
serum miR-21 level, the presence of circulating blasts at diagnosis
was associated with inferior PFS (Table 3). Multivariate analyses
revealed that circulating miR-21 (HR=4.189; 95% CI, 1.757 to
9.989; P=0.001) and the presence of circulating blasts at diagnosis
(HR=5.028; 95% CI, 1.569 to 16.118; P=0.007) remained
prognostic factors for PFS (Table 4).
Discussion
Although HMA have considerably improved treatment out-
comes for patients with MDS [2], responses and clinical outcomes
differ between patients [2,4,10,40,41]. Therefore, identification of
biomarkers that predict response to epigenetic therapy will
undoubtedly improve results of HMA treatment in MDS, making
individualized risk-adapted therapy possible. In this study, we
demonstrated for the first time that serum miR-21 was
significantly associated with response rate to HMA and PFS in
patients with MDS.
Currently, there are no clinical parameters or biomarkers that
can consistently predict response to HMA therapy or survival
benefit in patients with MDS. Several variables have been
reported to be associated with response to HMA [7,8], although
some of these findings were not confirmed in other series [9].
Previous low-dose cytarabine therapy [7,8], BM blasts [7,8],
abnormal karyotype [8], WPSS risk [41], doubling of the platelet
count after the first cycle of AZA [42], and the time interval from
diagnosis to initiation of HMA therapy [8] were associated with
overall response rate to AZA. Chromosome 7 abnormalities were
associated with a higher likelihood of response to DAC [4,43]. The
putative mechanism of action of HMA is inhibition of DNA
methyltransferase 1, leading to CpG dinucleotide hypomethylation
[44]. However, gene methylation patterns before or during
treatment did not correlate with clinical response to HMA
[15,45]. Recently it was demonstrated that mutations in the ten-
eleven-translocation 2 (TET2) [10,12], DNMT3A [11,12], and ASXL1
genes [12] predicted response to AZA, although these mutations
did not impact response duration or overall survival [46].
Because of their high stability in blood [30,31], circulating miRs
could be potentially utilized as noninvasive biomarkers for
diagnosis or prognosis in a variety of diseases. Furthermore,
serum or plasma miRs are more desirable than tissue miRs as
biomarkers, because they can be harvested easily and regularly
monitored [29–31]. Peripheral cytopenia is usually present in
MDS, and it is uncertain which cells are suitable targets for MDS
analysis. For those reasons, serum or plasma can be expected to be
better sources for miR assays in patients with MDS. However, few
studies have evaluated the prognostic relevance of miRs in MDS
Table 4. Multivariate analysis for overall response to HMA
and progression-free survival.
Variable ORR PFS
HR 95% CI P value HR 95% CI P value
IPSS cytogenetic 0.575 0.340–
0.974
0.040





Neutrophil counts 1.957 0.790–
4.847
0.147





Abbreviations: ORR, overall response rate; PFS, progression-free survival; HR,
hazard ratio; CI, confidence interval; IPSS, International Prognostic Scoring
System; miR-21, microRNA-21.
doi:10.1371/journal.pone.0086933.t004
Figure 4. Kaplan-Meier curves for overall survival and pro-
gression-free survival comparisons. (A) Overall survival and (B)
progression-free survival according to baseline serum miR-21 levels in
patients with myelodysplastic syndromes treated with hypomethylating
agents.
doi:10.1371/journal.pone.0086933.g004
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patients. Recently, it was shown that circulating let-7a and miR-16
were downregulated in MDS. Levels of let-7a and miR-16 were
significantly associated with PFS and OS [38], supporting the view
that circulating miRs are potential biomarkers in MDS. Quanti-
tative measurement of circulating miRs as a reliable biomarker
assay requires normalization to enable comparisons of miRNA
levels across different samples [41]. In this study, miR-192 was
identified through geNorm analysis as a suitable internal reference
gene for qPCR analysis of serum miRs in MDS patients and
healthy controls. In current study, we found low serum levels of
miR-21 in MDS patients compared with healthy individuals.
Further studies are necessary to evaluation whether the reduced
serum miR-21 level returns to normal levels after HMT.
Because of increasing evidence that circulating miR-21 may be
a useful biomarker for various cancers [29,30,36], we examined if
miR-21 is abnormally expressed in the sera of patients with MDS
and associated with response to HMA. Our study revealed that
serum miR-21 levels were significantly lower in MDS patients
compared to healthy controls. Previously Pons et al observed
higher levels of miR-21 at the cellular level in bone marrow and
peripheral blood samples from MDS patients compared with
normal donors [47]. Although we could not evaluate miR-21
simultaneously in sera, peripheral blood, and bone marrow cells,
these contradictory findings may be due to differences in the type
of sample examined in the miR-21 assay.
ROC analyses performed to assess the diagnostic power of
serum miR-21 yielded an AUC of 0.648 with 83.3% sensitivity
and 45.8% specificity for discriminating responders to HMA from
non-responders. Our study revealed that the response rate to
HMA was significantly lower in patients with high levels of serum
miR-21 compared with patients with low levels of serum miR-21.
In addition to serum miR-21, cytogenetic risk and the presence of
circulating blasts at diagnosis were observed to be highly
associated with poor response to HMA in our study. The time
interval from diagnosis to the initiation of HMA therapy did not
affect the response rate to HMA. Importantly, PFS was
significantly longer in HMA-treated patients with low serum
miR-21 compared to HMA-treated patients with high serum miR-
21. In multivariate analysis, serum miR-21 level remained an
independent predictor of PFS in patients treated with HMA.
The basis for the poor response of patients with high serum
miR-21 to HMA remains to be elucidated. Abnormal expression
of miR-21 may be related to transcriptional and post-transcrip-
tional regulation [48]. miR-21 regulates cell proliferation, differ-
entiation, and apoptosis by regulating target genes, including
tropomyosin 1 (TPM1), programmed cell death gene 4 (PDCD4),
transforming growth factor (TGF-b) pathway genes, Bcl-2, and
phosphatase and tensin homolog (PTEN) [33–35,49]. Activated
AKT has been linked to AZA responsiveness [13]. Based on these
findings, miR-21 may impact the sensitivity of ‘‘MDS cells’’ to
AZA by regulating PTEN/PI3K/AKT signaling. However, the
mechanisms regulating miR-21 expression in sera and the
functional roles of circulating miR-21 in MDS, especially in
relation to drug sensitivity, remain unclear. Based on these
findings, further exploration of molecular mechanism is needed.
Although we examined a retrospectively small number of
patients, serum miR-21 level could be serve as a potential
biomarker for predicting response to epigenetic treatment in
patients with MDS. PFS was significantly associated with serum
miR-21 levels in MDS patients treated with HMA. The clinical
potential of serum miR-21 as a biomarker in MDS should be
validated in a prospective study that includes a large cohort of
patients. Our findings may help clinicians identify patients who are
most likely to benefit from epigenetic therapy and may facilitate
development of risk-adaptive therapeutic strategies for MDS.
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